Teva Pharmaceutical Industries Target of Unusually High Options Trading (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) saw unusually large options trading activity on Monday. Stock investors purchased 37,691 put options on the company. This represents an increase of 38% compared to the typical daily volume of 27,275 put options.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. lifted their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. UBS Group increased their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Finally, Barclays boosted their price target on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.88.

Insiders Place Their Bets

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.55% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of large investors have recently made changes to their positions in TEVA. FMR LLC increased its holdings in Teva Pharmaceutical Industries by 49.5% in the third quarter. FMR LLC now owns 62,740,763 shares of the company’s stock valued at $1,130,589,000 after buying an additional 20,762,226 shares in the last quarter. Janus Henderson Group PLC increased its stake in Teva Pharmaceutical Industries by 7,945.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company’s stock valued at $86,350,000 after purchasing an additional 4,732,374 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Teva Pharmaceutical Industries by 237.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company’s stock worth $60,863,000 after purchasing an additional 2,376,668 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its position in Teva Pharmaceutical Industries by 6.8% during the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock worth $621,337,000 after purchasing an additional 2,204,623 shares in the last quarter. Finally, State Street Corp grew its holdings in Teva Pharmaceutical Industries by 10.0% in the third quarter. State Street Corp now owns 19,500,683 shares of the company’s stock valued at $351,402,000 after purchasing an additional 1,778,268 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 0.5 %

NYSE:TEVA opened at $22.21 on Tuesday. Teva Pharmaceutical Industries has a 1 year low of $10.34 and a 1 year high of $22.25. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The stock has a fifty day moving average price of $17.89 and a two-hundred day moving average price of $17.56. The stock has a market capitalization of $25.16 billion, a price-to-earnings ratio of -26.13, a PEG ratio of 0.99 and a beta of 0.79.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.